Hualan Biological Vaccine Inc. (SHE:301207)
China
· Delayed Price · Currency is CNY 19.25
-0.01 (-0.05%)
Apr 29, 2026, 3:04 PM CST
Hualan Biological Vaccine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2018 |
| Net Income | 187.51 | 182.92 | 205.52 | 859.97 | 519.63 | 620.97 | Upgrade
|
| Depreciation & Amortization | 141.08 | 141.08 | 140.38 | 140.33 | 135.43 | 68.93 | Upgrade
|
| Other Amortization | 0.14 | 0.14 | 1.67 | 4.53 | 6.15 | 1.55 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.2 | 0.2 | 0.14 | 0.2 | - | - | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.1 | 0.1 | 0.24 | 0.25 | -0.58 | 1 | Upgrade
|
| Loss (Gain) From Sale of Investments | -89.53 | -89.53 | -100.37 | -110.17 | -72.45 | -38.01 | Upgrade
|
| Provision & Write-off of Bad Debts | 30.75 | 30.75 | -9.4 | 21.33 | 28.77 | 1.04 | Upgrade
|
| Other Operating Activities | 159.83 | 60.77 | 80.23 | 101.28 | 162.54 | 146.32 | Upgrade
|
| Change in Accounts Receivable | 91.66 | 91.66 | 884.47 | -224.19 | -380.76 | 89.38 | Upgrade
|
| Change in Inventory | -27.74 | -27.74 | -97.32 | -101.23 | -211.49 | -195.39 | Upgrade
|
| Change in Accounts Payable | -22.12 | -22.12 | -642.07 | 170.28 | 117.16 | -116.66 | Upgrade
|
| Change in Other Net Operating Assets | -15.97 | -15.97 | -4.28 | 26.04 | 5.98 | 0.48 | Upgrade
|
| Operating Cash Flow | 460.78 | 357.13 | 468.04 | 888.02 | 288.66 | 569.33 | Upgrade
|
| Operating Cash Flow Growth | 24.87% | -23.70% | -47.29% | 207.64% | -49.30% | -17.93% | Upgrade
|
| Capital Expenditures | -9.65 | -9.7 | -51.6 | -62.6 | -92.65 | -636.06 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.19 | 0.19 | 0.04 | 0.09 | 0.31 | - | Upgrade
|
| Investment in Securities | 76.26 | 46.79 | -94.76 | -711.21 | -1,712 | -479 | Upgrade
|
| Other Investing Activities | 133.04 | 143.27 | 85.23 | 52.6 | 48.37 | 23.19 | Upgrade
|
| Investing Cash Flow | 199.84 | 180.54 | -61.08 | -721.11 | -1,756 | -1,092 | Upgrade
|
| Short-Term Debt Issued | - | - | - | 300 | 300 | 800 | Upgrade
|
| Total Debt Issued | - | - | - | 300 | 300 | 800 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | -300 | -500 | -500 | Upgrade
|
| Long-Term Debt Repaid | - | -300 | - | - | -1.08 | -1.1 | Upgrade
|
| Total Debt Repaid | -300 | -300 | - | -300 | -501.08 | -501.1 | Upgrade
|
| Net Debt Issued (Repaid) | -300 | -300 | - | - | -201.08 | 298.9 | Upgrade
|
| Issuance of Common Stock | - | - | 16.28 | - | 2,276 | - | Upgrade
|
| Repurchase of Common Stock | - | - | -106.79 | - | - | - | Upgrade
|
| Common Dividends Paid | -477.23 | -507.89 | -334.32 | -120 | -90.88 | -12.77 | Upgrade
|
| Other Financing Activities | - | - | - | -6.08 | -31.57 | - | Upgrade
|
| Financing Cash Flow | -777.23 | -807.89 | -424.82 | -126.09 | 1,952 | 286.13 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.02 | 0.12 | -0.08 | 0.11 | - | - | Upgrade
|
| Net Cash Flow | -116.63 | -270.1 | -17.95 | 40.94 | 485.25 | -236.4 | Upgrade
|
| Free Cash Flow | 451.14 | 347.43 | 416.45 | 825.42 | 196.01 | -66.73 | Upgrade
|
| Free Cash Flow Growth | 33.48% | -16.57% | -49.55% | 321.10% | - | - | Upgrade
|
| Free Cash Flow Margin | 37.44% | 28.89% | 36.93% | 34.24% | 10.74% | -3.65% | Upgrade
|
| Free Cash Flow Per Share | 0.76 | 0.58 | 0.70 | 1.37 | 0.33 | -0.12 | Upgrade
|
| Cash Interest Paid | - | - | - | 6.08 | - | - | Upgrade
|
| Cash Income Tax Paid | 11.4 | 54.13 | 151.5 | 192.05 | 172.31 | 296.12 | Upgrade
|
| Levered Free Cash Flow | 67.5 | 275.24 | 783.91 | 234.5 | -48.25 | -209.35 | Upgrade
|
| Unlevered Free Cash Flow | 69.09 | 276.84 | 787.73 | 238.3 | -41.57 | -201.03 | Upgrade
|
| Change in Working Capital | 30.7 | 30.7 | 149.63 | -129.7 | -490.85 | -232.46 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.